Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 89.1%

Neg 89.1% Neu 0% Pos 0%

Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4 to $3.